Investegate |Sanofi - Aventis Groupe Announcements | Sanofi - Aventis Groupe: Press Release: Positive Dupixent® (dupilumab) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine

Investegate announcements from Sanofi - Aventis Groupe, Press Release: Positive Dupixent® (dupilumab) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine

Related Keywords

Japan ,Paris ,France General ,France ,Eva Schaefer Jansen ,Corentine Driancourt ,Felix Lauscher ,Sharon Chen ,Vesna Tosic ,Nathalie Pham ,Sally Bain ,Evans Dellon ,Priya Nanduri ,Regeneron Pharmaceuticals Inc ,Twitter ,Regeneron Genetics Center ,Drug Administration ,Dupilumab Development Program ,Nasdaq ,Exchange Commission ,Committee For Medicinal Products Human ,European Union ,University Of North Carolina School Medicine ,European Medicines Agency ,Euronext ,Press Release ,Positive Dupixent ,New England Journal ,Medicinal Products ,Human Use ,North Carolina School ,Dupixent Eosinophilic Esophagitis ,Private Securities Litigation Reform Act ,Statement Regarding Forward Looking ,Forward Looking Statements ,Digital Media ,Regeneron Pharmaceuticals ,Product Candidates ,Investegate Announcements ,Investegate Company Announcements ,Sanofi Aventis Groupe ,Lobenewswire ,Lobenewswire And Globenewswire ,Nw ,